SAN DIEGO, Sept. 15, 2015 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Maryland on behalf of certain purchasers of shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged Securities Laws Violations by Northwest Biotherapeutics, Inc.
Investors who purchased shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) have certain options and for certain investors are short and strict deadlines running. Deadline: October 26, 2015. (NASDAQ:NWBO) investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff claims that defendants made certain allegedly false and/or misleading statements and/or allegedly failed to disclose that Northwest Biotherapeutics’ claims regarding positive results from its DCVax-Direct Trial were based on preliminary and unconfirmed trial results, that the DCVax-Direct Trial results on which Northwest Biotherapeutics reported had not been reviewed or analyzed by the hospitals conducting the trials, that Northwest Biotherapeutics’ statements about DCVax-Direct were derived from patient case report forms, which the hospitals were obliged to send to the Company only because it sponsored the study, that Northwest Biotherapeutics was the subject of an aggressive stock promotion campaign which included promoters using fictitious identities and false credentials, that German regulators required additional information from Northwest Biotherapeutics in order for its DCVax-L Trial to continue uninterrupted, and that as a result of the above, Northwest Biotherapeutics’ financial statements were materially false and misleading at all relevant times.
On June 19, 2014, an article was published that stated that "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.”
On July 7, 2014, a report stated that Northwest Biotherapeutics has been the subject of a massive promotional campaign which has seen the stock price soar. And, in some cases, authors have used fictitious identities and fake credentials within healthcare or finance. In fact they are simply paid writers.
On August 21, 2015, news broke that Northwest Biotherapeutics’ Phase 3 DCVax-L brain cancer treatment clinical trial in Germany was temporarily halted.
Those who purchased (NASDAQ:NWBO) shares have certain options and should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.